A Systematic Review of Neurologic Toxicity and Psychiatric Adverse Events associated with Immune Checkpoint Inhibitors

Abstract

In recent years, the emergence of immune checkpoint inhibitors (ICIs) has provided a new strategy for treating malignancies including lung cancer and melanoma. Neuropsychiatric irAEs is a rare adverse event, which is seldom reported and can become serious or even life-threatening. Hence, this study systematically and comprehensively reviewed the clinical manifestations and potential molecular mechanisms of neuropsychiatric irAEs associated with ICIs. In this study, we simply divided the neuropsychiatric irAEs into ICI neurological irAEs and ICI-related psychiatric adverse events. Seven central nervous system irAEs and four peripheral nervous system irAEs are summarized in details. We grouped and briefly described the possible mechanism of ICI-related psychiatric adverse events. In the future, more researches are needed to explore the pathogenesis and management of ICI-associated neuropsychiatric irAEs, which will allow patients to maximally benefit from ICI treatment.